Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.

The safety and overall survival seen in the ARC-10 trial lends further support to the firm's strategy of pairing domvanalimab and zimberelimab with chemo in STAR-121.

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Virologist Beata Halassy says self-treatment worked and was a positive experience — but researchers warn that it is not ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

AstraZeneca Plc started the week with a market valuation of about £171 billion ($222 billion). By the close on Thursday it ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

AstraZeneca's investment in South African trials has ... South Africa has contributed to several major studies, particularly in lung, breast, and prostate cancer research. One of the highlights is the ...

AstraZeneca's price plunge following a fraud investigation in China could be just the time to buy AZN stock as big picture ...

Leon Wang, executive vice president in charge of China and the broader Asian region, is being detained while the Chinese ...

Scientists have identified 16 genes that breast cancer cells use to survive in the bloodstream after they've escaped the low-oxygen regions of a tumor. Each is a potential therapeutic target to stop ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination ...